Hansa Biopharma AB (HNSA) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Hansa Biopharma AB (STO:HNSA), currently being evaluated. In recently, Hansa Biopharma AB generated N/A in revenue and N/A in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Hansa Biopharma AB is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (recently): N/A
- Free Cash Flow (recently): N/A
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.